Shanghai Pioneer Holding (HKSE:01345) 3-Year EBITDA Growth Rate : 22.00% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Shanghai Pioneer Holding 3-Year EBITDA Growth Rate?

Shanghai Pioneer Holding's EBITDA per Share for the six months ended in Dec. 2023 was HK$0.08.

During the past 12 months, Shanghai Pioneer Holding's average EBITDA Per Share Growth Rate was -35.70% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 22.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 17.50% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -5.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Shanghai Pioneer Holding was 27.40% per year. The lowest was -29.50% per year. And the median was -1.40% per year.

Competitive Comparison of Shanghai Pioneer Holding's 3-Year EBITDA Growth Rate

For the Pharmaceutical Retailers subindustry, Shanghai Pioneer Holding's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Pioneer Holding's 3-Year EBITDA Growth Rate Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Shanghai Pioneer Holding's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Shanghai Pioneer Holding's 3-Year EBITDA Growth Rate falls into.

Shanghai Pioneer Holding 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Shanghai Pioneer Holding (HKSE:01345) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Shanghai Pioneer Holding 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Shanghai Pioneer Holding's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Pioneer Holding (HKSE:01345) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Shanghai Pioneer Holding Ltd (HKSE:01345) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.15, Lane 88 Wuwei Road, Putuo District, Shanghai, CHN, 200331

Website

http://www.pioneer-pharma.com

Shanghai Pioneer Holding Ltd is an investment holding company. It is engaged in the marketing, promotion, sales, and channel management service for pharmaceutical products and medical devices in China. The company has a portfolio of pharmaceutical products, covering ophthalmology, pain management, cardiovascular, gastroenterology, immunology, gynecology, and other therapeutic areas, and medical devices covering several medical specialties, including ophthalmology, orthopedics, odontology, and wound care. The majority of its revenue derives from the Sales of pharmaceutical products segment. The group operates mainly in PRC.

Shanghai Pioneer Holding (HKSE:01345) Headlines

No Headlines